For the quarter ending 2026-03-31, IDXG made $9,032K in revenue. $721K in net income. Net profit margin of 7.98%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue, net | 9,032 | 9,225 | 8,756 | 9,232 |
| Cost of revenue | 3,128 | 3,180 | 3,317 | 3,956 |
| Gross profit | 5,904 | 6,045 | 5,439 | 5,276 |
| Sales and marketing | 2,177 | 2,113 | 2,087 | 2,910 |
| Research and development | 153 | 142 | 150 | 173 |
| General and administrative | 2,451 | 2,212 | 2,057 | 2,661 |
| Total operating expenses | 4,781 | 4,467 | 4,294 | 5,744 |
| Operating income from continuing operations | 1,123 | 1,578 | 1,145 | -468 |
| Note payable interest expense | - | 11 | 30 | 49 |
| Interest accretion expense | - | - | - | 0 |
| Other income, net | 10 | -32 | -115 | -16 |
| Income from continuing operations before tax | 1,133 | 1,535 | 1,000 | -533 |
| Provision for income taxes | 302 | -21,217 | -11 | 0 |
| Income from continuing operations | 831 | 22,752 | 1,011 | -533 |
| Loss from discontinued operations, net of tax | -110 | -95 | -100 | -107 |
| Net income | 721 | 22,657 | 911 | -640 |
| Net income attributable to common stockholders | - | 22,657 | - | - |
| Basic EPS | 0.03 | 5.117 | 0.21 | -0.14 |
| Diluted EPS | 0.03 | 0.818 | 0.03 | -0.14 |
| Basic Average Shares | 22,786,000 | 4,428,000 | 4,425,000 | 4,423,000 |
| Diluted Average Shares | 27,707,000 | 27,695,000* | 27,695,000 | 4,423,000 |
INTERPACE BIOSCIENCES, INC. (IDXG)
INTERPACE BIOSCIENCES, INC. (IDXG)